- Home
- VTEX vs LYEL Comparison
VTEX vs LYEL Comparison
Compare VTEX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTEX | LYEL |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 490.1M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VTEX | LYEL |
|---|---|---|
| Price | $3.65 | $23.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $6.16 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.1M | 95.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,000.00 |
| Revenue This Year | $8.28 | N/A |
| Revenue Next Year | $10.36 | N/A |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.84 | $0.39 |
| 52 Week High | $6.82 | $45.00 |
Technical Indicators
Market Signals| Indicator | VTEX | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 48.77 |
| Support Level | $2.92 | $21.27 |
| Resistance Level | $3.84 | $27.30 |
| Average True Range (ATR) | 0.16 | 2.19 |
| MACD | 0.09 | 0.14 |
| Stochastic Oscillator | 94.67 | 50.22 |
Price Performance
Historical ComparisonAbout VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.